KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bausch Health Companies (BHC) Research & Development (2016 - 2025)

Bausch Health Companies' Research & Development history spans 17 years, with the latest figure at $161.0 million for Q4 2025.

  • For Q4 2025, Research & Development fell 1.23% year-over-year to $161.0 million; the TTM value through Dec 2025 reached $544.0 million, down 11.69%, while the annual FY2025 figure was $629.0 million, 2.11% up from the prior year.
  • Research & Development for Q4 2025 was $161.0 million at Bausch Health Companies, up from $81.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $163.0 million in Q4 2024 and bottomed at $81.0 million in Q3 2025.
  • The 5-year median for Research & Development is $143.0 million (2023), against an average of $137.9 million.
  • The largest annual shift saw Research & Development grew 22.83% in 2023 before it crashed 44.52% in 2025.
  • A 5-year view of Research & Development shows it stood at $117.0 million in 2021, then grew by 21.37% to $142.0 million in 2022, then increased by 7.04% to $152.0 million in 2023, then grew by 7.24% to $163.0 million in 2024, then fell by 1.23% to $161.0 million in 2025.
  • Per Business Quant, the three most recent readings for BHC's Research & Development are $161.0 million (Q4 2025), $81.0 million (Q3 2025), and $159.0 million (Q2 2025).